<SEC-DOCUMENT>0001193125-13-462877.txt : 20131205
<SEC-HEADER>0001193125-13-462877.hdr.sgml : 20131205
<ACCEPTANCE-DATETIME>20131205081445
ACCESSION NUMBER:		0001193125-13-462877
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131205
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131205
DATE AS OF CHANGE:		20131205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				650271219
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		131258782

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d638501d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): December&nbsp;5, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><U>MEDNAX, INC.</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florida</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>001-12111</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>26-3667538</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Commission File</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Number)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sunrise, Florida
33323&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registrant&#146;s telephone number, including area code<U> (954)&nbsp;384-0175</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01&nbsp;Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2013, MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;), issued a press release (the &#147;Stock Split Release&#148;)
announcing that its Board of Directors authorized a two-for-one split (the &#147;Stock Split&#148;) of the Company&#146;s common stock, par value $0.01 per share (&#147;Common Stock&#148;). Shareholders of record on the effective date of
December&nbsp;19, 2013 will receive one additional share of Common Stock for each share of Common Stock then held, without any further action on the part of MEDNAX&#146;s shareholders.&nbsp;A copy of the Stock Split Release is attached hereto as
Exhibit 99.1 and is hereby incorporated in this Current Report by reference.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Stock Split, the remaining number of shares of Common
Stock registered under the Securities Act of 1933, as amended, pursuant to the Company&#146;s registration statements listed below will be proportionately adjusted to give effect to the Stock Split. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-181667 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-153397 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-151272 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-121125 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-101225 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement on Form S-8 No.&nbsp;333-85366 </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01&nbsp;Financial Statements and
Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:10%; font-size:10pt; font-family:Times New Roman">99.1&#151;Press Release of MEDNAX, Inc. dated December&nbsp;5, 2013 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: December 5, 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated December&nbsp;5, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d638501dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g638501mednax.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company
Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vivian Lopez-Blanco, 954-384-0175, x-5020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief
Financial Officer/Treasurer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>vivian_lopezblanco@mednax.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch, 443-213-0504 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles.lynch@westwicke.com</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE </U></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Announces Two-for-One Stock Split </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FORT LAUDERDALE, Fla., December&nbsp;5, 2013 &#150; MEDNAX, Inc. (NYSE: MD), the national medical group
specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialties and anesthesia physician services, today announced that its Board of Directors authorized a two-for-one split of MEDNAX&#146;s common stock. Shareholders
of record on the effective date of December&nbsp;19, 2013 will receive one additional share of MEDNAX common stock for each share of MEDNAX common stock then held, without any further action on the part of MEDNAX&#146;s shareholders. Shareholders do
not need to exchange existing stock certificates and will receive additional shares as a result of the stock split through the Direct Registration System on December&nbsp;20, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to complete the stock split, MEDNAX&#146;s Board of Directors has also authorized the amendment of the Company&#146;s Articles of Incorporation to
increase the number of authorized shares of common stock from 100&nbsp;million to 200 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are proud of the value MEDNAX has delivered to
our shareholders over the long-term. This stock split is the result of the Company&#146;s strong financial and stock price performance and reflects our continued confidence in MEDNAX&#146;s long-term growth opportunities, as well as our ongoing
determination to continue building long-term shareholder value,&#148; said Roger J. Medel, M.D., Chief Executive Officer of MEDNAX. Prior to this action, the most recent MEDNAX stock split occurred in 2006. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s common stock trades on the New York Stock Exchange under the symbol MD and is expected to
trade on a post-split basis at the opening of trading on December&nbsp;20, 2013. Upon completion of the stock split, MEDNAX will have approximately 101&nbsp;million shares of common stock outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national medical group
comprised of the nation&#146;s leading providers of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery
of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of
MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 330 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric critical care physician
subspecialists to provide a clinical care continuum. Pediatrix is also the nation&#146;s largest provider of newborn hearing screens. In 2007, MEDNAX expanded into anesthesia services. Today, American Anesthesiology includes more than 1,700
anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 2,200
physicians in 34 states and Puerto Rico. Additional information is available at www.mednax.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating
to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These
statements are often characterized by terminology such as &#147;believe&#148;, &#147;hope&#148;, &#147;may&#148;, &#147;anticipate&#148;, &#147;should&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;will&#148;, &#147;expect&#148;,
&#147;estimate&#148;, &#147;project&#148;, &#147;positioned&#148;, &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of
historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or
revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual
results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX&#146;s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled
&#147;Risk Factors&#148;, as well MEDNAX&#146;s current reports on Form 8-K, filed with the Securities and Exchange Commission. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g638501mednax.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g638501mednax.jpg
M_]C_X``02D9)1@`!``$`>`!X``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`(<`Z0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`();VV@E$
M4LZ(YZ`FE=(=F3TQ!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`&!XBU.YLGBBMVV;ADG'-93DUHBX),TM)NWO=.CFD'SG(/OBK
MB[HF2LR[5""@#SZY2YGU2165FF+GCOG-<SNV;K1'>6Z-%;11N<LJ`$^^*Z%H
MC!DM,`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`BN;
MF*T@::9MJ+2;LKC2N<EJ.N07Y"O9@JOW26YK&4[]#11L;.AZK:W$2VL<?DL@
MX7.0?QJX23T)E%K4V:T(,;7=7?3E2*$#S7&<GL*SG+EV+C&YRKZG>22>8T[;
M_P"\#@_I67,S2R+]AXBNK>4"=S-$>H8\CZ&J4VA.*9V,4J31++&<HPR#6ZU,
M=A]`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&!XFWS+
M:VL>2TC$@?D/ZUE4Z(N&FIS>HV$FG77D2,"<`@BLVK.QHG<+7S;5HKQ.BR8_
M'KC_`#[TEIJ#UT/08Y%EB21#E6`(/M748;')ZT!?>(8[=,G&U#C_`#[UA+65
MC6.D3#F01S.BG*@X!J"S:328;KP^MS`")X\EN>HS_A5\MXW1%[2L:GA>9GT]
MXF/^K?CV!_R:NF]"9K4W*T("@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@"CJU^VG6?G*F]BVT9Z#_.*F3Y5<J*NQ-*U)=2MC)LV.IPPHC+F025
MB+9]MUI)E&8+92-W8OW'^?2EO(-D<QKUTMUJDC)@JGR@^N/\FLIN[-(JR)=!
M"7$LMC-S',O'J&'((_6B&N@2TU-ZV74-.MVM1#YX'$3J1@?7-:+FBK$.SU(H
M=/\`[*M;B_N'WW6TG/8$_P!:%'E5V%[Z(X\G+$U@:F_X7O3'<M:,?DD&0/<?
M_6K6F[.Q$UI<V-$M?LIO`!A?.*K]!_\`KJX*UR).]C5#*20&!(ZC/2K)%H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`YW6];A3?9K"LPZ,6Z`^
MU93FMC2,>IF:5)>73?8K1A#&<LY'7'UZU$;O1%.RU9N:D\FG::EI90R,Q7&Y
M5)QZGCN:TE[JLB%J[LXY(I)7*HC,WH!FL34O:&LG]K0,B,0K<X'054-R9;'>
M5T&)B>)YO+TQ8Q_RT<?I_D5G4=D7#<K:)H4$EEY]TF\R#Y1G&!ZTH05KL<I6
M=D9*PMI>OI'V208)],_X5%N616Z.BO+J72I9MX8VTV2CCK&Q'^36C?*0E<P]
M(N_LUV\J[YIW!5(QW)]3^%9Q=F7)71V,6_RE\TCS,?-CIFN@Q'T`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`#7#&-@A`;'!/8T`<MKT-O96,%I&`TS'
M>S$?,>V3_GM6,TDK&L;MW*GAN7RM713QO4K_`%_I4P=F.>QVI^Z:Z#$YOPO;
M_O;FX(Z84?U_D*RIKJ:39+HL/D:W?H!P,X]N>*(*TF$MD=!6IF<]XAC:ZO[&
MU7^+/ZD?X&LIZM(TCHFS?1%C144851@#T%:F9S?B.V(U"VG4??\`E)]P?_K_
M`*5C-:IFD'H7_$DHCTAE[R,`/Y_TJYNR%#<R/"IC%](K`>84^4G]:SI[E3V.
MNK<R"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`BN//$)^SA#)VWG@4
MG?H->9EVVADWAN[^43R9R%Q\HJ%#6[*<M+(9=62)XBLY(8PI8%FVC`X[T->\
MK`G[K-RM"#.T6#R;23Y<%I6_0X_I405D5)W8ZTMS'JM_,00'V8_+FFE9L&]$
M7ZHDH?9GDUO[0R_NXX@JGU8D_P!/YU-O>N5?2Q?JB2CJ=J;I+?:N3',K?AWJ
M9*Y2=ANJ69NQ;+LWHLP+C_9HDKV"+L%WI,4\J3PL;>=.CH/Z4.-]04K:%V(.
ML:B1@S@<D#&?PJB1]`!0`4`%`!0`4`%`!0`4`%`'!?$GQ/JGAM=..FS+'YV_
M?N0-G&W'7ZFMZ4%*]SFKU)0MRG`?\+1\4_\`/Y'_`-^5_P`*V]C`YOK%3N>Q
M>%M?B\2:#!?I@28VS(/X''4?U_&N6<>5V.ZG-3C<V))$AB>61@D:`LS'H`.I
MJ#38\2UCXJ:U)JMP=,F2*R#8B5HE)P.YR._6NR-&-M3SY8B=_=V*7_"T/%/_
M`#^1_P#?E?\`"G[&!/UBIW#_`(6AXI_Y_(_^_*_X4>Q@'UBIW#_A:'BG_G\C
M_P"_*_X4>Q@'UBIW#_A:'BG_`)_(_P#ORO\`A1[&`?6*G<3_`(6=XGW[OM<6
M[&,^0F<?E1[&'8/K%3N/C^*?BA&R;F%QZ-"N/TH]C`/K%0ZC0_B_%)*L.LV0
MA!_Y;09('U4\_D:SE0_E-H8G^9'4>,?$,NG^#3J^CW,;%F3RY``P()K.G"\K
M2-JLW&'-$\M_X6AXI_Y_(_\`ORO^%=/L8'']8J=SUGP;XIA\4:.LV52\BPL\
M8['U'L:Y:D.1G;2J*<;]3H9"5C8CJ`369J>#R?$_Q0DK*+R/`./]2O\`A7;[
M&!YOUBIW/3/AWKVH>(-!FNM1E6259R@*J%XP#V^M<]6*B[(ZZ$W.-V</XT^(
M.KV_B:YM=(OC#:V_[K"JIW,/O'D>O'X5M3I1Y;LYZM:2G:+,[1?B3KT6LVC:
MCJ#36?F`2H44?*>">!VZU4J4;:(F%>:DKO0]V!#*"I!!&017$>B>/^*_%WB_
MPSKDME)>(T1^>&0P+\Z'IVZ]C77"$)*YPU*M2$K7&>&/BAJ;:[!#K4\;V4IV
M,PC"[">C<#I1.BK>Z*GB)<WO;'L,LL<,+S2.$C12S,3P`.]<AWWL>)ZO\5-;
MDU6X.F3)#9!L1*8E)VCN<COUKLC1BEJ>?+$3O[NQO>!/$7BKQ1JK>?>*MA;C
M,K"%1D]E!QU_PJ*D(01I1G4F]7H=@TFOQ/$JYE5\;F,:@I\YST_V1C\:Q]TW
M]]'0U!J%`!0!Y5\9_P#5Z1]9/_9:Z</U.+%=#R:NHXSL?AWXH_X1_7A#</BQ
MNR$DR>$/\+?A_(UE5AS(WH5.26NQV?Q6\4?9+%=#M9/WUP-TY!^ZG8?C_(>]
M8T87?,S?$5++D1XW76<(Y%WNJYQDXH`]87X-1%0?[9;D?\\/_KUR^W\CM^J^
M8O\`PIF+_H,M_P!^/_KT>W\@^J^9YUXFT8>'_$%UIBS><("OSE<9RH/3\:WA
M+F5SEJ1Y)<I8\)>&6\5:J]BET+8K$9-Q3=G!`QC(]:)SY%<=.G[1V.KO/@[J
M4,):TU&"X<#[C*4S]#S62KKJC9X62V9Y]>V5SIUY):7D+0SQG#(PY%;IIJZ.
M9IQ=F;_AN\FU"QNO"\DQ$-X-UN">$F7E1]&QC\1425GS&D'=<G<YEE*,588(
M."*T,C6\->(+KPUK$5];$E1\LL>>'7N#43BI*S+IS<)71]$V.I6NKZ0E]9R!
MX)HR0>X]0?<5PM.+LSU%)2C='S'/_KY/]XUZ!Y!ZEX(UA=!^&>JZ@2`Z3,(P
M>[E5"_K7/4CS5$CLHRY*39Y6[M)(SN268Y)/<UTG&-Z'T-`'T#\.=;_MGPG`
MLC9N+3]P_/)`^Z?RQ^1KAJQY9'I4)\T/0E\=>%U\3:$R1*/MUOEX&]3W7\?Y
MXI4Y\C'6I\\?,^>W1HI&1U*NIP0>H-=YYAU][X^O+SP3!H1W"8'9+-G[\8^Z
M/KV/T]ZR5-*?,;NLW#D.6L+&XU*_@LK6,O/,P1%]ZT;25V8I-NR/I#PWH-OX
M<T6#3X`"5&9'Q]]SU/\`GM7GSDY.YZM."A&R-:I+"@`H`*`/*OC/_J](^LG_
M`++73A^IQ8KH>7Z?9OJ&HV]E&P5YY%C4GH"3@5TMV5SDBKNPR[M9K&[EM;B,
MQS0L4=3V(H3NKH333LQ+BXFNYC+<2O+(0`68Y)P,#]!0E;8&V]RYJ6C7&E6M
MA+<C:UY%YRH1R%R0,_7&:2DG>Q4HN*5^IGJ2K`C@CI5$G3#XA^*P,?VN_P#W
M[3_"L_90[&OMZG<4?$3Q7_T%W_[]I_\`$T>RAV#V]3N1^/7:3QA=NYRS1PL3
MZDQ)13^$*WQLV_A#_P`C;-_UZM_Z$M17^$TPWQGM]<9Z!Y+\9-/B233=050)
M7#1.?[P&"/YFNJ@]T<6*CLSS;2I7@U>RFC.'CF1E/N"#70]4<D79HN>*8$M_
M%FJPQC"+=28'I\QJ8:Q1516FRGJ.FW6E70M[J/8Y177'1E(R"*::>Q,HN+LS
MJ?`'C`^'[Q[*\D/]FW/#$\^4W9OIZ_\`UJSJT^976YM1J\CL]CCIB#.Y!R-Q
MK4P-"35W/AN'1TR(Q<-._N<`#\L'\Z7+[URN;W>4M>#]&.N^*+*S(S%OWR_[
MB\G_``_&E.7+&Y5*//-(TOB3HHTCQ9,\:!;>['G)@8`)^\/SS^=32E>)5>'+
M,M?"W6_[,\3BSD;$%\OEGT#CE3_,?C2K1O&Y6'GRSMW/=:XCT3Q;XL:!;:=J
ML.J6[HAO<^9%GG<.K`>A_G]:ZZ,FU8\_$P47S+J>=5T',>N_"/0+46DVN.Z2
M7!8Q(HY\H=\^Y_E]:Y:\G\)VX:"MS'J-<QV!0`4`%`!0!Y5\9_\`5Z1]9/\`
MV6NG#]3BQ70\[\,_\C3I7_7U'_Z$*WG\+.:G\:/1OBMX5\R,>(+./YD`2Y4#
MJ.@;^A_"L*,_LLZL33^VCDOA_P"%CXCUP/.A^P6I#S''#'LOX_RS6M6?*C"C
M3YY:[&S\8@%U[3P``!:X`';YC44/A9IBOB1YU&H:15/0G%;G*>WK\)?#A127
MO,D?\]1_\37)[>1Z'U:`[_A4GAS^_>?]_1_\31[>0?5H'FGQ#C$/C>_B7.U!
M$HSZ"-16]+X$<E?2HS7^$/\`R-LW_7JW_H2U-?X33#?&>V2S101-)-(L<:C)
M9S@#\:XST+V/"_B3XIM_$.KPP6+[[2S!"N.CL>I'MP!7;2@XK4\VO44W9;(Y
M[PU9"^\1643G;$L@DE8]%1?F8_D#5S=HLSIJ\DBMJMZ=1UJ\O3Q]HG:3'IDY
MJHJR2)D[ML]H\1^$4\3>#[!H5"ZA;VR&%O[PVC*GZ_SKCA/DD^QZ%2ESP5MS
MPR6-X97BD4HZ$JRD8(([5V'G;#:8!0!L>'_$E_X9N9;C3Q#YLJ["TB;L#.>*
MB4%+1EPJ.#NB;Q#XNU/Q-'`NHB`^0249(]I&>H_2B,%#8<ZDI[F)#*\$T<T3
M%9(V#*P[$=#5&>Q]):5XAM;WPK#K<LBQP^3OE/92/O#\P:X'%J7*>K&:<.8\
M%\5>(9O$NN37TF5B^[#&3]Q!T']3]:[81Y%8\VI-SE<QVAE2))6C81N2%8C@
MD=<'\15$'4^`?%1\-:VJSN?L%SA)AV7T;\/Y9K.I#F1M1J<DO(^@58,H92"I
M&01WKA/3%H`*`"@`H`\J^,_^KTCZR?\`LM=.'ZG%BNAYWX9_Y&G2O^OJ/_T(
M5O/X6<U/XT?2TT,=Q!)!,@>*12K*>A!ZBO/V/5:OH9V@Z#9>'--%C9*=FXNS
M-]YB?7]!^%5*3D[LF$%!61Y;\8_^0_8?]>W_`+,:Z:'PLX\5\2/-P2""."*Z
M#E-@>*_$`&!K-[_W_;_&HY(]B_:3[A_PEGB#_H,WO_?]O\:.2/8/:3[F;=7=
MQ>W+W%U,\TS_`'G=LD\8ZU226B(;;=V-@N)[9]\$SQ/C&48@XHL";6Q)/?7=
MRH6>YEE4=G<FBR0-M[C;6TN+VX2WM87FF<X5$7)-#=MP2;=D>A7GA&;PG\/K
MZ]N6VZE=;(W"G_5QEN5S[\9_*L%/GFDMCJ=)TZ;;W/.!]X5T'(?4&C_\@2P_
MZ]X__017FRW9[$?A1YS\4/!OF(_B#3X_G4?Z4BCJ/[_^/Y^M=%&I]EG+B*7V
MT>25U'$/AB>>9(8U+2.P50.Y-+8-SUV+X-V1A0RZI.)-HW!4&,]\5S>W?8[?
MJJ[CO^%-:?\`]!6X_P"^%I>W?8?U5=SRC4["72]3N;&8?O+>0H??!ZUU)W5S
MBDN5V9977[Z/PX^AK)BS>;SF'<G'3Z<9^M+E7-S#YWR\O0AT?2KC6M5M]/M5
MS+,V,]E'<GV`HDU%781BY.R/<M:\#V=WX+31+1`LEJNZW<\$OWS_`+W.?K[5
MQQJ-2YF>A.BG#E1X%+%);S/#*A22-BK*1@@CM7:>;:Q[)\+/%?V^Q_L.\DS<
MVZY@)_C3T^H_E]*Y:T+/F1W8>I=<K/1ZYSK"@`H`*`,+Q%X3TWQ.+<:@91Y&
M[9Y;[>N,]O:KA-PV,YTXSW,FS^&'A^QO8+N$W7FP.LBYE&,@Y':K=:35C-8>
M"=T=G6)T!0!SOB'P7I7B:[BN;\S>9$FQ?+?`QDGT]ZTC4<%9&4Z49N[,?_A4
MWAOUN_\`OZ/\*KV\C/ZM`/\`A4WAOUN_^_H_PH]O(/JT`_X5-X;];O\`[^C_
M``H]O(/JT`_X5-X;];O_`+^C_"CV\@^K0#_A4WAOUN_^_H_PH]O(/JT"2+X5
M>&8FRT5Q+[--Q^F*/;3&L-31TNF:%I>BH5TZQAM\]65?F/U/4UFY.6YM&$8[
M(-<T6TU_3'T^]+^2S!CL;!XHC)Q=T*<%-69RW_"IO#8[W?\`W]'^%:>WD8_5
MH';6\"6MM%;QYV1($7/7`&*Q>IT)65A[*KH58`J1@@]"*!G$R_"KPU+,\@6Y
M3<2=JR``>PXK;VTCG^K0)]-^&N@:5J,%]`MPTL#;T#R`C(Z<8I.K)JPXT(1=
MT=A61N%`'*ZU\/\`0]>U-]0NUF6=P`WEN`#@8ST]*UC5E%61C.A";NS/_P"%
M3>&_6[_[^C_"G[>1'U:!L>'_``5H_AFYEN;%)#-(NS=*VX@>@XJ95)2T9I"E
M&#NCHJS-3D]8^'>@ZUJ<M_<I,DTN"_E.%!/KC'6M8U915D8RH0D[LAL/AIH>
MF7T-[:2WD<\+!D82CK^72AUI-68EAX1=T=E61N%`!0`4`8FK_:AJ5NUJW[Q$
M+;?[V,\5E*_,K%QM;4CLK]+K76G#%8Q:Y8$_=(/-"E>5P:LBI::B6U07+W"F
M.Y9HS'GE!P%.*2EK<;6EBPVE6ZZY':AI/*,)<C?WS3Y5S6%?2XR>>2S?45A<
MJ=T:*Q/W1@\_I2;M>P[7L37VG+I=G]LMIY!/&02S-D/SCG\Z;CRJZ$G?0@6\
MN+;5[NZ`9K=2@E3N`5'/X47:;8[)JQ-9Z@MOI^IW0<,/M#^62>#G&*%*R;$U
M=I":!=&.X>T>X68NHD5@<X..1_GTH@[.P274O:`Q;2(B22<MU^M5#X12W(O$
M7F_9K986*R-,`"#CG!I3V")G7%_>7I@!0Q+`X67/&7Y_PJ')LI)(1Q$^HW@F
MMKN8B4@&$$@4^K#H6%LHKK5U@?S4B6U5E4M@@Y[^].R;L*]D07LDUO::C9&9
MI$A,91B>1DC@TGHFAKHR]]G&J:E<QW$K>3!A5C5L?B?RJK<S=Q;+0?=G^Q=)
MF"SNY=ML>\\KGT^G)H?NH2U96TJY"6UY8F=93&A='4Y!!'./H:479-#:ZFMI
M9)TV$GT/\ZN'PHF6Y5U:21[BSLD=HUG8[V7T':E+HAQ[E&(VMK>2V\*W<3%'
M`#_<8@'G]*E63LAZM%!'A^SQ"V-R+]F^7!X/-0K6TW*-:.W_`+6OKH7;OL@(
M18U.!GU_2M+<S=R;V6A3GDDMTN[(S,Z02(48GD`]JEZ70UW-35F(NM.`)&9Q
MG%7+=$QZF%&]N8I-KW'VT/\`($S[5EI;S+.NAW^1'YO^LVC=]<<UT(R'T`%`
M!0!7>U#WL5SN(,8(QCK_`)S2MK<=]+%.;1(I)YY8I6A,Z[7``(Z@G\\5+@A\
MQ+-I%G+:?9Q"B<`!@HR,4W%-6$FT2)8A;V*Z:4LZ1>7R.OO1;6X7TL,.EPN]
MV9"76XQE?3%'*M0N0)H@)19[N:>&,Y6-CQ^/K2Y.['S%J*PCCN;J8MO%QC<I
M'`P,4TK-BN5(]!@C"Q^8QA$IE\LCJ<``?I2Y$A\Q8FTN!YH)8E6"2)MP**.?
M44W%"N5X=&EMT"1:C,B#HH%)0MLQ\WD7+RR6\$(9ROE2!Q@=<535Q)V%NK-+
MF,)G9APY('4TFK@G8J-I$@N)98;Z6+S6W%5%+EUT8^81]'D:=9UOI4DV!"PZ
MD9HY?,.8<VB0&PDM5D<&4AGD/+$@YHY%:P<VH^YTL2W'VB"XDMYB,,R=&^HI
MN.MT"=M"./1(4DC9Y7E",6*OR&8]S2Y$',2S:5`\Z2Q8@95*D(H`8$8YIN*%
M<B@TF:`H%U&;8ISLQQUZ4E%KJ-ROT+=[91WT01RRE3E64X*FJ:N).Q5CTC][
MYL]U)/(%*H6_A!&*E1[L=Q[Z3')8Q6Y<AHCN20#D'.:.72P<VMQLVD^9/]HB
MNI()RH#LG1_<BAQZH$^@Y-'MDLY;=MS^:<N['+$^M/D5K!S.XVWTGR[B.::Z
MEG,7W`YX6DHV=V%RS96:V4)C5BV6+9(IQ5A-W+-4(*`"@`H`*`"@`H`*`"@`
LH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
